Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia

Texto completo
Autor(es):
Gouvea-Junqueira, Danielle [1] ; Falvella, Ana Caroline Brambilla [1] ; Antunes, Andre Saraiva Leao Marcelo [1] ; Seabra, Gabriela [1] ; Brandao-Teles, Caroline [1] ; Martins-de-Souza, Daniel [2, 3, 1, 4] ; Crunfli, Fernanda [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas - Brazil
[2] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria, Sao Paulo - Brazil
[3] Univ Estadual Campinas, Expt Med Res Cluster, Campinas - Brazil
[4] DOr Inst Res & Educ IDOR, Sao Paulo - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo de Revisão
Fonte: FRONTIERS IN PSYCHIATRY; v. 11, APR 30 2020.
Citações Web of Science: 1
Resumo

Oligodendrocytes are the glial cells responsible for the formation of the myelin sheath around axons. During neurodevelopment, oligodendrocytes undergo maturation and differentiation, and later remyelination in adulthood. Abnormalities in these processes have been associated with behavioral and cognitive dysfunctions and the development of various mental illnesses like schizophrenia. Several studies have implicated oligodendrocyte dysfunction and myelin abnormalities in the disorder, together with altered expression of myelin-related genes such as Olig2, CNP, and NRG1. However, the molecular mechanisms subjacent of these alterations remain elusive. Schizophrenia is a severe, chronic psychiatric disorder affecting more than 23 million individuals worldwide and its symptoms usually appear at the beginning of adulthood. Currently, the major therapeutic strategy for schizophrenia relies on the use of antipsychotics. Despite their widespread use, the effects of antipsychotics on glial cells, especially oligodendrocytes, remain unclear. Thus, in this review we highlight the current knowledge regarding oligodendrocyte dysfunction in schizophrenia, compiling data from (epi)genetic studies and up-to-date models to investigate the role of oligodendrocytes in the disorder. In addition, we examined potential targets currently investigated for the improvement of schizophrenia symptoms. Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3 beta (GSK3 beta) signaling, contributing to oligodendrocyte survival and functioning. In conclusion, there is strong evidence linking oligodendrocyte dysfunction to the development of schizophrenia. Hence, a better understanding of oligodendrocyte differentiation, as well as the effects of antipsychotic medication in these cells, could have potential implications for understanding the development of schizophrenia and finding new targets for drug development. (AU)

Processo FAPESP: 19/22398-2 - O papel da síntese de colesterol no mecanismo de ação da clozapina em modelos experimentais para esquizofrenia
Beneficiário:Fernanda Crunfli
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 18/10362-0 - Avaliação do efeito de antipsicóticos e do canabidiol em cultura de oligodendrócitos tratados com cuprizona: implicações para mielinização
Beneficiário:Ana Caroline Brambilla Falvella
Linha de fomento: Bolsas no Brasil - Mestrado
Processo FAPESP: 18/03673-0 - Efeitos bioquímicos de canabinóides em oligodendrócitos: implicações para a esquizofrenia
Beneficiário:Daniel Martins-de-Souza
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 17/25055-3 - Investigação sobre o papel das hnRNPs em oligodendrócitos e suas implicações na esquizofrenia
Beneficiário:Caroline Brandão Teles Rodrigues
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 17/25588-1 - Da compreensão básica a biomarcadores clínicos para a esquizofrenia: um estudo multidisciplinar centrado na neuroproteômica
Beneficiário:Daniel Martins-de-Souza
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 18/25439-9 - Perfil proteômico de células progenitoras neurais e neuroesferas infectadas com cepas de Zika vírus e Dengue vírus
Beneficiário:Danielle Gouvêa Junqueira
Linha de fomento: Bolsas no Brasil - Mestrado